Search

Your search keyword '"Retinal Neovascularization therapy"' showing total 37 results

Search Constraints

Start Over You searched for: Descriptor "Retinal Neovascularization therapy" Remove constraint Descriptor: "Retinal Neovascularization therapy" Topic angiogenesis inhibitors Remove constraint Topic: angiogenesis inhibitors
37 results on '"Retinal Neovascularization therapy"'

Search Results

1. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.

2. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.

Catalog

Books, media, physical & digital resources

3. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.

4. Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications.

5. Incidence of submacular haemorrhage (SMH) in Scotland: a Scottish Ophthalmic Surveillance Unit (SOSU) study.

6. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.

7. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.

8. Treatment of Foveal Neovascularization in a Patient With Type 1 Diabetes.

9. Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.

10. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).

11. Development of Multigenic Lentiviral Vectors for Cell-Specific Expression of Antiangiogenic miRNAs and Protein Factors.

12. In vitro and in vivo inhibition of proangiogenic retinal phenotype by an antisense oligonucleotide downregulating uPAR expression.

13. Results of a Randomized Clinical Trial of Aflibercept vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Is It Time to Retire Your Laser?

14. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.

15. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.

16. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.

17. INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.

19. Response to Carifi et al.'s letter.

20. [BOON (Bonn ophthalmology online network). Concept of an integrative databank for monitoring patients under intravitreal therapy].

21. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.

22. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?

23. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.

24. Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy.

25. Managing retinal vein occlusion.

26. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.

27. [Anti-angiogenic therapy associated with laser photocoagulation in the treatment of subretinal neovascular membrane: case report].

28. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications.

29. Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.

30. Biotech in a blink.

31. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.

32. Role of intravitreal bevacizumab in the management of Eales' disease.

33. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial.

34. Gene therapy for ocular neovascularization.

35. [Transfer of endostatin gene for inhibition of retinal angiogenesis in mice].

36. Gene transfer for the treatment of neovascular ocular disease (an American Ophthalmological Society thesis).

37. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy.